货号:A238567
同义名:
西沙比利
/ (±)-Cisaprid; R 51619
Cisapride是一种 5-HT4 受体激动剂,IC50 为 9.4 nM,具有胃促动力作用,能刺激肠道释放乙酰胆碱。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | 5-HT ↓ ↑ | 5-HT1 ↓ ↑ | 5-HT2 ↓ ↑ | 5-HT3 ↓ ↑ | 5-HT5 ↓ ↑ | 5-HT6 ↓ ↑ | 5-HT7 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Desvenlafaxine |
++
5-HT, Ki: 40.2 nM |
98% | |||||||||||||||||
| Lamotrigine |
+
5-HT (human platelets), IC50: 240 μM 5-HT (rat brain synaptosomes), IC50: 474 μM |
98% | |||||||||||||||||
| Venlafaxine | ✔ | 99% | |||||||||||||||||
| Fluvoxamine maleate | ✔ | 99% | |||||||||||||||||
| Iloperidone | ✔ | 99% | |||||||||||||||||
| Ziprasidone HCl | ✔ | 98+% | |||||||||||||||||
| Atomoxetine HCI |
+
5-HT, Ki: 77 nM |
98% | |||||||||||||||||
| Dapoxetine HCl | ✔ | 97% | |||||||||||||||||
| Trazodone | ✔ | 98+% | |||||||||||||||||
| Clomipramine HCl | ✔ | 98% | |||||||||||||||||
| Mirtazapine | ✔ | 99+% | |||||||||||||||||
| Escitalopram oxalate |
+++
5-HT, Ki: 0.89 nM |
97% | |||||||||||||||||
| Duloxetine | ✔ | 97% | |||||||||||||||||
| Sertraline HCl |
++
5-HT, Ki: 13 nM |
98% | |||||||||||||||||
| Citalopram HBr |
+++
serotonin reuptake, IC50: 1.8 nM |
98% | |||||||||||||||||
| Latrepirdine 2HCl | ✔ | GluR | 99% | ||||||||||||||||
| Fluoxetine HCl | ✔ | 99.5% | |||||||||||||||||
| Paroxetine HCl | ✔ | AChR | 99% | ||||||||||||||||
| BMY 7378 |
++
5-HT1D, pIC50: 5.9 5-HT1A, pIC50: 6.4 |
+
5-HT2, pIC50: 5.5 |
97% | ||||||||||||||||
| Flibanserin |
+++
5-HT1A, Ki: 1 nM |
+
5-HT2A, Ki: 49 nM |
95% | ||||||||||||||||
| LY310762 |
+
5-HT1D, Ki: 249 nM |
99%+ | |||||||||||||||||
| Cyclobenzaprine HCI | ✔ | 99% | |||||||||||||||||
| Blonanserin |
+++
5-HT2, Ki: 3.98 nM |
99% | |||||||||||||||||
| Cyproheptadine HCl |
++++
5-HT2, IC50: 0.6 nM |
99+% | |||||||||||||||||
| Olanzapine | ✔ | 99+% | |||||||||||||||||
| Pimavanserin hemitartrate |
+++
5-HT2A, pIC50: 8.7 |
99% | |||||||||||||||||
| Ketanserin |
+++
5-HT2C (Human), Ki: 2.5 nM 5-HT2C (Rat), Ki: 50 nM |
99%+ | |||||||||||||||||
| Loxapine succinate |
++
5-HT2 (bovine), Ki: 6.6 nM 5-HT2 (human), Ki: 6.8 nM |
98% | |||||||||||||||||
| Agomelatine | ✔ | 98% | |||||||||||||||||
| Clozapine | ✔ | 98% | |||||||||||||||||
| Amitriptyline |
+
5-HT2, Ki: 235 nM |
SERT | 99% | ||||||||||||||||
| PRX-08066 maleate |
+++
5-HT2B, IC50: 3.4 nM |
98+% | |||||||||||||||||
| RS-127445 |
++++
5-HT2B, pIC50: 10.4 5-HT2B, pKi: 9.5 |
99%+ | |||||||||||||||||
| Sarpogrelate HCl |
++++
5-HT2A, Kd: 2.1 nM 5-HT2C, Kd: 1.1 nM |
98% | |||||||||||||||||
| Tropisetron | ✔ | 99% | |||||||||||||||||
| Ramosetron HCl |
++++
5-HT3 receptor, Ki: 0.091 nM |
98% | |||||||||||||||||
| Ondansetron | ✔ | 99% | |||||||||||||||||
| Granisetron | ✔ | 98% | |||||||||||||||||
| Alosetron HCl | ✔ | 98% | |||||||||||||||||
| Ondansetron HCl dihydrate | ✔ | 98% | |||||||||||||||||
| VUF10166 |
++++
5-HT3A, Ki: 0.04 nM 5-HT3AB, Ki: 22 nM |
99%+ | |||||||||||||||||
| Azasetron HCl |
++++
5-HT3, IC50: 0.33 nM |
99% | |||||||||||||||||
| Asenapine maleate |
+++
5-HT1B, pKi: 8.4 5-HT1A, pKi: 8.6 |
++++
5-HT2C, pKi: 10.46 5-HT2A, pKi: 9.75 |
+++
5-HT5A, pKi: 8.84 |
++++
5-HT6, pKi: 9.6 |
++++
5-HT7, pKi: 9.94 |
97% | |||||||||||||
| Risperidone |
++
5-HT1D, Ki: 84.6 nM 5-HT1B, Ki: 14.9 nM |
++++
5-HT2C, Ki: 12 nM 5-HT2A, Ki: 61.9 nM |
+
5-HT5A, Ki: 206 nM |
++
5-HT7, Ki: 6.6 nM |
98% | ||||||||||||||
| SB 271046 HCl |
+++
5-HT6, pKi: 8.92 |
99%+ | |||||||||||||||||
| Intepirdine |
++++
5-HT6, pKi: 9.63 |
99%+ | |||||||||||||||||
| SB-269970 HCl |
++
5-HT7, pKi: 8.3 |
98+% | |||||||||||||||||
| BRL 15572 |
++
5-HT1B, pKi: 6.1 5-HT1D, pKi: 6 |
++
5-HT2B, pKi: 6.2 5-HT2A, pKi: 6.6 |
+
5-HT6, pKi: 5.9 |
+
5-HT7, pKi: 6.3 |
95% | ||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Cisapride (R 51619) is an orally active 5-HT4 receptor agonist with an EC50 value of 140 nM. Cisapride is also an hERG blocker with an IC50 value of 9.4 nM. It functions as a gastroprokinetic agent, stimulating gastrointestinal motor activity[1][2][3][4]. |
| 体内研究 | Cisapride (0.1-1 mg/kg; i.v., once) enhances antral and colonic motility in conscious dogs[3]. Cisapride (2 mg/kg (i.p.); 4 mg/kg, (oral administration); once) does not exhibit significant differences in macroscopic features, histopathological features, cytokine profile, or bodyweight changes compared to TNBS-treated rats[4]. |
| 体外研究 | Cisapride (1-100 nM) exhibits potent hERG blockade with an IC50 value of 9.4 nM[1]. Cisapride (1-100 nM) demonstrates efficacy at the 5-HT4 receptor with an EC50 value of 140 nM[1]. Cisapride demonstrates dose-dependent inhibition of Kv4.3 potassium channels expressing CHO cells, with an IC50 value of 9.8 μM, across concentrations of 0.3, 1, 3, 10, and 30 μM[2]. |
| Concentration | Treated Time | Description | References | |
| human liver microsomes | 5 μM | 30 min | To investigate the metabolism pathways and major metabolites of cisapride. Results showed that cisapride is primarily metabolized by CYP3A4, forming the major metabolite norcisapride. | Br J Pharmacol. 2000 Apr;129(8):1655-67 |
| Rat proximal colon mucosa-submucosa or mucosa-only preparations | 100 μM | To investigate the effects of luminal 5-HT on colonic anion secretion, it was found that luminal 5-HT increased HCO3− secretion via 5-HT4 receptor activation, and was not affected by TTX or atropine. | Br J Pharmacol. 2015 Oct;172(19):4655-70 | |
| HEK293 cells | 19.5, 39.1, 156, 313, 625, 1250, 2500, 5000, 10000, 20000 nM | Evaluate the inhibitory effect of Cisapride on hERG channels, IC50 value was 938 nM | Br J Pharmacol. 2016 Oct;173(19):2819-32 | |
| HEK293 cells | 0.1, 0.3, 1, 3, 10, 30, 100 nM | Evaluate the inhibitory effect of Cisapride on hERG channels, IC50 value was 6.8 nM | Br J Pharmacol. 2016 Oct;173(19):2819-32 | |
| iPSC-derived cardiomyocytes | 0.1 μM, 1 μM, 10 μM, 100 μM | 24 h | To evaluate the effects of cisapride on calcium flux and QT prolongation in cardiomyocytes. Results showed that cisapride induced changes in calcium flux, manifested as QT prolongation, with some cells exhibiting Torsade's-like arrhythmias. | ALTEX. 2018;35(4):441-452 |
| Oocytes expressing HERG channels | 0.133 µM | To study the blocking effect of Cisapride on HERG channels, showing an IC50 of 0.133 µM. | Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12329-33 |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00699894 | Postoperative Nausea and Vomit... 展开 >>ing 收起 << | Not Applicable | Withdrawn(Logistical difficult... 展开 >>ies running the study) 收起 << | - | United States, New York ... 展开 >> Long Island Jewish Medical Center/Schneider's Children Hospital New Hyde Park, New York, United States, 11040 收起 << |
| NCT02524496 | - | Completed | - | - | |
| NCT01281540 | Gastroparesis | Phase 4 | Terminated(Sponsor request) | - | - |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.15mL 0.43mL 0.21mL |
10.73mL 2.15mL 1.07mL |
21.46mL 4.29mL 2.15mL |
|
| CAS号 | 81098-60-4 |
| 分子式 | C23H29ClFN3O4 |
| 分子量 | 465.95 |
| SMILES Code | O=C(C1=CC(Cl)=C(C=C1OC)N)N[C@@H]2[C@@H](CN(CC2)CCCOC3=CC=C(C=C3)F)OC |
| MDL No. | MFCD00869327 |
| 别名 | 西沙比利 ;(±)-Cisaprid; R 51619; Propulsid; Pridesia; Presid; Prepulsid; Kinestase; Kaudalit |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(225.35 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1